Dr. Reddy's Laboratories Management

Management Kriterienprüfungen 3/4

Dr. Reddy's Laboratories' CEO ist Erez Israeli, ernannt in Apr 2018, hat eine Amtszeit von 6.08 Jahren. besitzt direkt 0.041% der Aktien des Unternehmens, im Wert von ₹402.64M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.1 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Erez Israeli

Geschäftsführender

₹197.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	6.3yrs
Eigentum des Geschäftsführers	0.003%
Durchschnittliche Amtszeit des Managements	6.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Erez Israeli im Vergleich zu den Einnahmen von Dr. Reddy's Laboratories verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	₹197m	n/a	₹56b
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b
Dec 31 2019	n/a	n/a	₹16b
Sep 30 2019	n/a	n/a	₹27b
Jun 30 2019	n/a	n/a	₹21b
Mar 31 2019	₹123m	n/a	₹19b

Vergütung im Vergleich zum Markt: ErezDie Gesamtvergütung ($USD2.35M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD1.03M).

Entschädigung vs. Einkommen: ErezDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Erez Israeli (56 yo)

6.3yrs

Amtszeit

₹197,090,000

Vergütung

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019. Mr. Israeli served as Chief Operating Officer, Global Head Generics & PSAI Business and Memb...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gunupati Prasad	Co-Chairman	38.3yrs	₹186.28m	13.08% ₹ 140.0b
Kallam Reddy	Chairman of the Board & Member of the Management Council	31.5yrs	₹116.17m	13.62% ₹ 145.8b
Erez Israeli	CEO & Member of the Management Council	6.3yrs	₹197.09m	0.0031% ₹ 33.0m
Parag Agarwal	CFO & Member of Management Council	3.6yrs	₹64.66m	keine Daten
Krishna Venkatesh	Global Head of Quality and Pharmacovigilance & Member of the Management Council	less than a year	₹6.15m	keine Daten
Deepak Sapra	CEO of API & Services & Member of Management Council	no data	₹41.90m	0.0027% ₹ 28.7m
Venkata Motupalli	CEO of Branded Markets - India & Emerging Countries and Member of Management Council	no data	₹82.74m	0.016% ₹ 168.4m
Archana Bhaskar	EVP, Head of Corporate Communications	7.1yrs	₹65.21m	0.0063% ₹ 68.0m
Sanjay Sharma	Executive VP	6.9yrs	₹66.05m	keine Daten
Patrick Aghanian	CEO of European Generics & Member of Management Council	no data	₹63.09m	keine Daten
Mannam Venkatanarasimham	Deputy CFO & Member of the Management Council	no data	₹48.82m	0.0057% ₹ 60.7m
Sushrut Kulkarni	Global Head of Integrated Product Development Organisation & Member of the Management Council	no data	₹55.63m	0.000020% ₹ 214.1k

6.3yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 500124 ist erfahren und erfahren (durchschnittliche Amtszeit: 6.1 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gunupati Prasad	Co-Chairman	38.3yrs	₹186.28m	13.08% ₹ 140.0b
Kallam Reddy	Chairman of the Board & Member of the Management Council	31.5yrs	₹116.17m	13.62% ₹ 145.8b
Kalpana Morparia	Lead Independent Director	17.1yrs	₹16.68m	0.0065% ₹ 69.4m
R. Rajgopalan	Member of the Scientific Advisory Board	no data	₹8.36m	keine Daten
Arun Kumar	Independent Director	1.9yrs	₹18.77m	keine Daten
Shikha Sharma	Additional Independent Director	5.5yrs	₹13.34m	keine Daten
K. Reddy	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Leo Puri	Independent & Non Whole-time Director	5.8yrs	₹17.10m	keine Daten
Kodumudi Krishnan	Additional Independent Director	2.5yrs	₹14.18m	keine Daten
Alpna Seth	Independent Director	1.5yrs	₹8.25m	keine Daten
Penny Wan	Additional Independent Director	2.5yrs	₹17.10m	keine Daten
Claudio Albrecht	Director	1.2yrs	₹16.09m	keine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: 500124Die Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).

Dr. Reddy's Laboratories Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr. Reddy's Laboratories Limited Announces Change in Management

Recent updates

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dividend of ₹40.00 announced

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Price target increased by 7.7% to ₹5,388

Dr. Reddy's Laboratories Limited Announces Management Changes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Upcoming dividend of ₹40.00 per share at 0.8% yield

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Consensus EPS estimates increase by 17%

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Upcoming dividend of ₹30.00 per share

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market